Overview

Hematopoietic and lymphoid malignancys most frequently harbor alterations in DNMT3A, TET2, TP53, SRSF2, and KRAS [2].

Most Commonly Altered Genes in Hematopoietic and Lymphoid Malignancy

DNMT3A Mutation, TET2 Mutation, TP53 Mutation, SRSF2 Mutation, and SRSF2 Codon 95 Missense are the most common alterations in hematopoietic and lymphoid malignancy [2].

Top Alterations in Hematopoietic and Lymphoid Malignancy

Significant Genes in Hematopoietic and Lymphoid Malignancy

ABL1 +

AFF1 +

BCL2 +

BCL6 +

BCR +

DEK +

ELL +

ERBB2 +

FLT3 +

IDH1 +

KMT2A +

MECOM +

MLF1 +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

MYC +

NPM1 +

NUP214 +

PBX1 +

RPN1 +

TCF3 +

TP53 +

Disease Details

Parent(s)
Hematopoietic and Lymphoid System Neoplasm
Children
Lymphoma, Monomorphic Post-Transplant Lymphoproliferative Disorder, Malignant Mastocytosis, Lymphangiosarcoma, Leukemia, Malignant Bone Marrow Neoplasm, Malignant Lymph Node Neoplasm, Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA/PDGFRAB or FGFR1 or PCM1-JAK2, Splenic B-Cell Lymphoma/Leukemia, Unclassifiable, Spleen Cancer, and Polymorphic Post-Transplant Lymphoproliferative Disorder

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.